BlueCross BlueShield of SC, the dominant carrier, has been inconsistent with covering Wegovy and Zepbound
My insurance company, Blue Cross Blue Shield of Massachusetts, will suspend coverage beginning in 2026 a move common among many insurers, who are losing money as the popularity of the drug, wildly effective as it is, soars
Based on how GLP-1-based treatment programs are generally managed clinically, and on published research on semaglutide and tirzepatide as a medication class, people beginning this class of therapy may notice changes along roughly the following pattern - though many fall outside these ranges in either direction
Older adults, those with complex polypharmacy, or patients prone to gastrointestinal intolerance may fare better on semaglutides simpler incretin profile, while younger, severely obese individuals might accept tirzepatides potency despite higher initial nausea rates often
10.1016/j.bbrc.2021.05.011 51 ThavarajahP.SeeC.-T.VandenbergA